Clinical Trial Results:
Pilot Trial: The effects of intravenous heme arginate on HO-1 expression and oxidative stress in the human heart
Summary
|
|
EudraCT number |
2013-000887-27 |
Trial protocol |
AT |
Global end of trial date |
13 Jun 2017
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
04 Apr 2020
|
First version publication date |
04 Apr 2020
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
2.0
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT02314780 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Medical University of Vienna
|
||
Sponsor organisation address |
Währinger Gürtel 18-20, Vienna, Austria, 1090
|
||
Public contact |
Prof. Dr. Martin Andreas, Medical University of Vienna, +43 14040069660, martin.andreas@meduniwien.ac.at
|
||
Scientific contact |
Prof. Dr. Martin Andreas, Medical University of Vienna, +43 14040069660, martin.andreas@meduniwien.ac.at
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
29 Aug 2018
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
13 Jun 2017
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
13 Jun 2017
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
The main objective of the trial was to evaluate the effects of heme arginate administration in two different doses on myocardial HO-1 induction.
|
||
Protection of trial subjects |
The trial was conducted according to the principles of Good Clinical Practice and the Declaration of Helsinki and in agreement with the Austrian laws and regulation. The Ethics Committee of the Medical University of Vienna approved the trial.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
29 Mar 2015
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Austria: 31
|
||
Worldwide total number of subjects |
31
|
||
EEA total number of subjects |
31
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
8
|
||
From 65 to 84 years |
23
|
||
85 years and over |
0
|
|
|||||||||||||||||||||
Recruitment
|
|||||||||||||||||||||
Recruitment details |
Patients who were scheduled for elective surgical aortic valve replacement were assessed for eligibility after hospitalization. A sample size of 24 subjects was calculated. The ethical board approved up to 36 subjects with an interim analysis of the first 24 subjects. The trial was stopped after the interim analysis because of significant results. | ||||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||||
Screening details |
A total of 31 patients signed the informed consent to participate in the trial. Of them, 27 subjects were randomized. | ||||||||||||||||||||
Pre-assignment period milestones
|
|||||||||||||||||||||
Number of subjects started |
31 | ||||||||||||||||||||
Number of subjects completed |
27 | ||||||||||||||||||||
Pre-assignment subject non-completion reasons
|
|||||||||||||||||||||
Reason: Number of subjects |
organizational reasons: 3 | ||||||||||||||||||||
Reason: Number of subjects |
other reason: 1 | ||||||||||||||||||||
Period 1
|
|||||||||||||||||||||
Period 1 title |
overall trial (overall period)
|
||||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||||
Blinding used |
Double blind | ||||||||||||||||||||
Roles blinded |
Subject, Investigator, Carer | ||||||||||||||||||||
Blinding implementation details |
A non-transparent infusion kit was used for the administration of the investigational medicinal products in order to maintain the blind.
|
||||||||||||||||||||
Arms
|
|||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||||
Arm title
|
Normosang (high dose) | ||||||||||||||||||||
Arm description |
24 hours prior to the planned surgical aortic valve replacement, subjects received a single intravenous infusion of heme arginate at a dose of 3 mg/kg diluted to 110 ml with 0,9% sodium chloride. | ||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||
Investigational medicinal product name |
Normosang
|
||||||||||||||||||||
Investigational medicinal product code |
1-27260
|
||||||||||||||||||||
Other name |
heme arginate
|
||||||||||||||||||||
Pharmaceutical forms |
Concentrate for solution for infusion
|
||||||||||||||||||||
Routes of administration |
Intravenous drip use
|
||||||||||||||||||||
Dosage and administration details |
24 hours prior to the planned surgical aortic valve replacement, heme arginate at a dose of 3 mg/kg diluted to 110ml with 0,9% sodium chloride was administered at a single intravenous infusion using an infusion pump. To avoid any local irritation from drug infusion, 250ml 0,9% sodium chloride solution was administered thereafter.
|
||||||||||||||||||||
Arm title
|
Normosang (low dose) | ||||||||||||||||||||
Arm description |
24 hours prior to the planned surgical aortic valve replacement, subjects received a single intravenous infusion of heme arginate at a dose of 1 mg/kg diluted to 110 ml with 0,9% sodium chloride. | ||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||
Investigational medicinal product name |
Normosang
|
||||||||||||||||||||
Investigational medicinal product code |
1-27260
|
||||||||||||||||||||
Other name |
heme arginate
|
||||||||||||||||||||
Pharmaceutical forms |
Concentrate for solution for infusion
|
||||||||||||||||||||
Routes of administration |
Intravenous drip use
|
||||||||||||||||||||
Dosage and administration details |
24 hours prior to the planned surgical aortic valve replacement, heme arginate at a dose of 1 mg/kg diluted to 110ml with 0,9% sodium chloride was administered at a single intravenous infusion using an infusion pump. To avoid any local irritation from drug infusion, 250ml 0,9% sodium chloride solution was administered thereafter.
|
||||||||||||||||||||
Arm title
|
Placebo | ||||||||||||||||||||
Arm description |
24 hours prior to the planned surgical aortic valve replacement, subjects received a single intravenous infusion of an equivalent volume of 0,9% sodium chloride solution. | ||||||||||||||||||||
Arm type |
Placebo | ||||||||||||||||||||
Investigational medicinal product name |
0,9% Sodium chloride solution
|
||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||
Other name |
|||||||||||||||||||||
Pharmaceutical forms |
Solution for infusion
|
||||||||||||||||||||
Routes of administration |
Intravenous drip use
|
||||||||||||||||||||
Dosage and administration details |
24 hours prior to the planned surgical aortic valve replacement, an equivalent volume of sodium chloride solution was administered at a single intravenous infusion using an infusion pump.
|
||||||||||||||||||||
|
|||||||||||||||||||||
Notes [1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same. Justification: 31 subjects were enrolled in the trial. Of them, 4 patients (3 patients for organizational reasons and 1 patient for other reasons) were excluded from the trial prior to randomization and drug administration. |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Normosang (high dose)
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
24 hours prior to the planned surgical aortic valve replacement, subjects received a single intravenous infusion of heme arginate at a dose of 3 mg/kg diluted to 110 ml with 0,9% sodium chloride. | ||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Normosang (low dose)
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
24 hours prior to the planned surgical aortic valve replacement, subjects received a single intravenous infusion of heme arginate at a dose of 1 mg/kg diluted to 110 ml with 0,9% sodium chloride. | ||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
24 hours prior to the planned surgical aortic valve replacement, subjects received a single intravenous infusion of an equivalent volume of 0,9% sodium chloride solution. | ||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Normosang (high dose)
|
||
Reporting group description |
24 hours prior to the planned surgical aortic valve replacement, subjects received a single intravenous infusion of heme arginate at a dose of 3 mg/kg diluted to 110 ml with 0,9% sodium chloride. | ||
Reporting group title |
Normosang (low dose)
|
||
Reporting group description |
24 hours prior to the planned surgical aortic valve replacement, subjects received a single intravenous infusion of heme arginate at a dose of 1 mg/kg diluted to 110 ml with 0,9% sodium chloride. | ||
Reporting group title |
Placebo
|
||
Reporting group description |
24 hours prior to the planned surgical aortic valve replacement, subjects received a single intravenous infusion of an equivalent volume of 0,9% sodium chloride solution. |
|
|||||||||||||||||
End point title |
Myocardial HO-1 mRNA levels (atrial tissue) | ||||||||||||||||
End point description |
The right atrial appendage was clamped and cut for cannulation before cardiopulmonary bypass. The tissue samples were snap-frozen in the operating theater after sampling.
|
||||||||||||||||
End point type |
Primary
|
||||||||||||||||
End point timeframe |
intraoperative
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
HO-1 mRNA concentrations (appendage) | ||||||||||||||||
Comparison groups |
Normosang (low dose) v Placebo v Normosang (high dose)
|
||||||||||||||||
Number of subjects included in analysis |
24
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
other | ||||||||||||||||
P-value |
= 0.001 | ||||||||||||||||
Method |
ANOVA | ||||||||||||||||
Confidence interval |
|
|||||||||||||||||
End point title |
Myocardial HO-1 mRNA levels (ventricular tissue before aortic cross-clamping) | ||||||||||||||||
End point description |
A small biopsy was taken from the right ventricular free wall directly before aortic cross-clamping. The tissue samples were snap-frozen in the operating theater after sampling.
|
||||||||||||||||
End point type |
Primary
|
||||||||||||||||
End point timeframe |
intraoperative
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
HO-1 mRNA level (ventricle pre) | ||||||||||||||||
Comparison groups |
Normosang (high dose) v Normosang (low dose) v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
24
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
other | ||||||||||||||||
P-value |
= 0.002 | ||||||||||||||||
Method |
ANOVA | ||||||||||||||||
Confidence interval |
|
|||||||||||||||||
End point title |
Myocardial HO-1 mRNA levels (ventricular tissue after aortic cross-clamping) | ||||||||||||||||
End point description |
A small biopsy was taken from the right ventricular free wall after aortic clamp release before weaning from cardiopulmonary bypass. The tissue samples were snap-frozen in the operating theater after sampling.
|
||||||||||||||||
End point type |
Primary
|
||||||||||||||||
End point timeframe |
intraoperative
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
HO-1 mRNA (ventricle post) | ||||||||||||||||
Comparison groups |
Normosang (high dose) v Normosang (low dose) v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
24
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
other | ||||||||||||||||
P-value |
= 0.002 | ||||||||||||||||
Method |
ANOVA | ||||||||||||||||
Confidence interval |
|
|||||||||||||||||
End point title |
Myocardial HO-1 protein concentrations (atrial tissue) | ||||||||||||||||
End point description |
The right atrial appendage was clamped and cut for cannulation before cardiopulmonary bypass. The tissue samples were snap-frozen in the operating theater after sampling.
|
||||||||||||||||
End point type |
Primary
|
||||||||||||||||
End point timeframe |
intraoperative
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
HO-1 protein concentration (appendage) | ||||||||||||||||
Comparison groups |
Normosang (high dose) v Normosang (low dose) v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
24
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
other | ||||||||||||||||
P-value |
< 0.001 | ||||||||||||||||
Method |
ANOVA | ||||||||||||||||
Confidence interval |
|
|||||||||||||||||
End point title |
Myocardial HO-1 protein concentrations (ventricular tissue before aortic cross-clamping) | ||||||||||||||||
End point description |
A small biopsy was taken from the right ventricular free wall directly before aortic cross-clamping. The tissue samples were snap-frozen in the operating theater after sampling.
|
||||||||||||||||
End point type |
Primary
|
||||||||||||||||
End point timeframe |
intraoperative
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
HO-1 protein concentrations (ventricle pre) | ||||||||||||||||
Comparison groups |
Normosang (high dose) v Normosang (low dose) v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
24
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
other | ||||||||||||||||
P-value |
= 0.138 | ||||||||||||||||
Method |
ANOVA | ||||||||||||||||
Confidence interval |
|
|||||||||||||||||
End point title |
Myocardial HO-1 protein concentrations (ventricular tissue after aortic cross-clamping) | ||||||||||||||||
End point description |
A small biopsy was taken from the right ventricular free wall after aortic clamp release before weaning from cardiopulmonary bypass. The tissue samples were snap-frozen in the operating theater after sampling.
|
||||||||||||||||
End point type |
Primary
|
||||||||||||||||
End point timeframe |
intraoperative
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
HO-1 protein concentrations (ventricle post) | ||||||||||||||||
Comparison groups |
Normosang (high dose) v Normosang (low dose) v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
24
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
other | ||||||||||||||||
P-value |
= 0.696 | ||||||||||||||||
Method |
ANOVA | ||||||||||||||||
Confidence interval |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Adverse events occuring within 96 hours after the administration of Normosang/sodium chloride solution were reported.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
22.0
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Normosang (high dose)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
24 hours prior to the planned surgical aortic valve replacement, subjects received a single intravenous infusion of heme arginate at a dose of 3 mg/kg diluted to 110 ml with 0,9% sodium chloride. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Normosang (low dose)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
24 hours prior to the planned surgical aortic valve replacement, subjects received a single intravenous infusion of heme arginate at a dose of 1 mg/kg diluted to 110 ml with 0,9% sodium chloride. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
24 hours prior to the planned surgical aortic valve replacement, subjects received a single intravenous infusion of 100 ml 0,9% sodium chloride solution. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
Biopsy samples were small and protein concentration could not be measured in every sample. The sample size is small for a 3-arm randomized controlled trial. | |||
Online references |
|||
http://www.ncbi.nlm.nih.gov/pubmed/30354231 |